期刊文献+

曲美他嗪对经皮冠状动脉介入治疗术后SOD、MDA、hs-CRP和cTnI的影响 被引量:13

Effect of trimetazidine on SOD,MDA,hs-CRP and cTnI of patients undergoing percutaneous coronary intervention
下载PDF
导出
摘要 目的探讨曲美他嗪对经皮冠状动脉介入治疗(PCI)患者超氧化物歧化酶(SOD)、丙二醛(MDA)、血清高敏C-反应蛋白(hs-CRP)及肌钙蛋白(IcTnI)的影响。方法选择因冠状动脉狭窄病变需行PCI术的不稳定型心绞痛(UA)患者41例,随机分成两组。常规治疗基础上,术前3d加服曲美他嗪后行PCI术20例为曲美他嗪组,未服曲美他嗪行PCI术21例为常规治疗组。两组在行PCI术前3d、术后24h均检测血清SOD、MDA、hs-CRP和cTnI的水平。结果曲美他嗪组PCI术后24h较术前3d的hs-CRP、MDA和cTnI水平降低(P<0.01),SOD水平升高(P<0.01);常规治疗组PCI术后24h较术前3d的hs-CRP、MDA和cTnI水平升高(P<0.01),SOD水平降低(P<0.01);曲美他嗪组常较规治疗组术后24hhs-CRP、MDA和cTnI水平降低(P<0.01),SOD水平升高(P<0.01)。结论曲美他嗪能够抑制PCI术后炎症反应,减少膜脂质的过氧化损伤,从而减轻PCI术造成的心肌细胞损伤,预防再狭窄,为PCI术患者提供心脏保护。 ObjectiveTo determine the effect of trimetazidine on SOD,MDA,hs-CRP and cTnI in the patients undergoing percutaneous coronary intervention(PCI).Methods The study consisted of 41 patients with unstable angina who underwent elected PCI for stenotic lesions of the coronary artery.The patients were randomly assigned to either trimetazidine group or conventional one.Twenty cases taking trimetazidine 3 days before PCI surgery were enrolled into trimetazidine group,while twenty-one cases receiving conventional therapy without taking trimetazidine were enrolled into conventional therapy group.3 days before PCI and 24 hours after PCI,serum SOD,MDA,hsCRP and cTnI levels were detected in both groups.ResultsThe levels of CRP,MDA and cTnI 24 hours after PCI surgery were lower than those 3 days before PCI in trimetazidine group(P〈0.05),but SOD level was higher(P〈0.05).The levels of CRP,MDA and cTnI 24 hours after PCI were higher than those 3 days before PCI in the conventional therapy group(P〈0.05),but SOD level was lower(P〈0.05).Compared with the conventional therapy group,the levels of hs-CRP,MDA and cTnI in the trimetazidine group 24 hours after PCI surgery were lower(P〈0.05),SOD level was higher(P〈0.05).ConclusionTrimetazidine can inhibit the inflammatory response,reduce membrane lipid peroxidation injury,thereby reduce myocardial cell injury caused by PCI,prevent stenosis,and provide cardiac protection for PCI patients.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2010年第17期2643-2645,2649,共4页 China Journal of Modern Medicine
关键词 曲美他嗪 经皮冠状动脉介入治疗 超氧化物歧化酶 丙二醛 高敏C-反应蛋白 肌钙蛋白I trimetazidine percutaneous coronary intervention superoxide dismutase malondialdehyde highsensitivity C-reactive protein cardiac troponin I
  • 相关文献

参考文献10

  • 1BONELLO L, SBRAGIA P, AMABILE N, et al. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention [J]. 2007, 93(6): 703-707.
  • 2HUANG P, FENG L, OLDHAM EA, et al. Nature, 2000, 407 (6802): 390-395.
  • 3AGHDASSI E, ALLARD JP. Breath alkanes as a marker of oxidative stress in different clinical conditions [J]. Free Radic Biol Med, 2000, 28(6): 880-886.
  • 4MASERI A. Inflammation, atherosclerosis, and ischemic events exploring the hidden side of moon [J]. N Eng Med, 1997, 336 (10): 1014-1016.
  • 5LI JR, HU DY. CRP and cardiovascular disease [J]. Chinese Joumal of Cardiovascular Review, 2005, 3(5): 388-391.
  • 6RIFAI N, RIDKER PM. High sensitivity C-reative protein:a novel and promising maker of coronary heart disease[J]. Current Opinion in Lipidology, 2002, 13(4): 383-389.
  • 7WANG CH, LI SH, WEISEL RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle [J]. Circulation, 2003, 107(13): 1783-1790.
  • 8HATYORI Y, MATSUMMURA M, KASSAI K. Vascular smooth muscle cell activation by C-reactive protein [J]. Cardiovase Res, 2003, 58(1): 186-195.
  • 9LOPASCHUK GD, BARR R, THOMAS PD, et al. Beneficial effects of trimetazidine in exvivo working ischemic hears are due to a stimulation of glucose oxidation secondary to inhibition of longchain 3-ketoacyl coenzyme a thiolase [J]. Circ Res, 2003, 93 (3): 33-37.
  • 10SZWED H. Clinical benefits of trimetazidine in patients with recurrent angina [J]. Coron Artery Dis, 2004, 15 (Suppl 1): S17-21.

同被引文献121

引证文献13

二级引证文献78

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部